CompareMarketResearchRequest a sample
Home / Food and Beverage / NMN (Nicotinamide Mononucleotide)

Food and Beverage · Market report

NMN (Nicotinamide Mononucleotide) Market Size, Share and Forecast 2026-2036

The global NMN (nicotinamide mononucleotide) market is worth USD 327 mn in 2026 and is forecast to reach USD 848 mn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Capsules and tablets is the largest by form segment.

USD 327 mnMarket size 2026
USD 848 mnForecast 2036
10.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global NMN (nicotinamide mononucleotide) market is worth USD 327 mn in 2026 and is forecast to reach USD 848 mn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Capsules and tablets is the largest by form segment.

ScopeNicotinamide mononucleotide (NMN) sold as a bulk ingredient and as finished capsules, powders and sublingual products for healthy-ageing use.
IndustryFood and Beverage
Value 2025USD 300 mn
Value 2026USD 327 mn
Value 2036USD 848 mn
CAGR 2026-203610.0%
Volume 2026334 tonnes
Volume 20361,059 tonnes
Average price 2026USD 980,000 per tonne
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

NMN (Nicotinamide Mononucleotide) market size and forecast, 2026-2036

Exhibit 1The global NMN (nicotinamide mononucleotide) market is forecast to grow from USD 327 mn in 2026 to USD 848 mn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 10.0%
NMN (Nicotinamide Mononucleotide) market value, 2025 to 2036Market value by year. 2025: USD 300 mn; 2026: USD 327 mn; 2027: USD 360 mn; 2028: USD 396 mn; 2029: USD 435 mn; 2030: USD 479 mn; 2031: USD 527 mn; 2032: USD 579 mn; 2033: USD 637 mn; 2034: USD 701 mn; 2035: USD 771 mn; 2036: USD 848 mn. Compound annual growth rate 2026 to 2036: 10.0%.2025327 mn2026527 mn2031848 mn203610.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 327 mn
2027USD 360 mn
2028USD 396 mn
2029USD 435 mn
2030USD 479 mn
2031USD 527 mn
2032USD 579 mn
2033USD 637 mn
2034USD 701 mn
2035USD 771 mn
2036USD 848 mn

NMN (Nicotinamide Mononucleotide) market segmentation

By form

Exhibit 2Capsules and tablets is the largest segment by form, with 52.0% of 2026 revenueEstimated share of 2026 global revenue, by form
NMN (Nicotinamide Mononucleotide) market share by form, 2026Share of 2026 revenue by form. Capsules and tablets: 52.0%; Powder: 22.0%; Sublingual and liquid: 14.0%; Combination formulas: 12.0%.Capsules and tablets52.0%Powder22.0%Sublingual and liquid14.0%Combination formulas12.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Capsules and tablets52.0%49.3%USD 170 mn9.4%
Powder22.0%20.9%USD 72 mn9.4%
Sublingual and liquid14.0%17.4%USD 46 mn12.4%
Combination formulas12.0%12.5%USD 39 mn10.4%

By channel

Exhibit 3Online and direct to consumer adds the most revenue by channel, growing from USD 183 mn in 2026 to USD 523 mn by 2036Estimated revenue in USD by channel, 2026 and 2036 forecast
NMN (Nicotinamide Mononucleotide) market by channel, 2026 and 2036Revenue by channel in 2026 and 2036. Online and direct to consumer: USD 183 mn in 2026, USD 523 mn in 2036, change +186%; Pharmacy and specialty retail: USD 78 mn in 2026, USD 171 mn in 2036, change +117%; Clinics and practitioners: USD 39 mn in 2026, USD 102 mn in 2036, change +161%; Other channels: USD 26 mn in 2026, USD 52 mn in 2036, change +98%.20262036 forecastChangeOnline and direct to consumer+186%183 mn523 mnPharmacy and specialty retail+117%78 mn171 mnClinics and practitioners+161%39 mn102 mnOther channels+98%26 mn52 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Online and direct to consumer56.0%61.7%USD 183 mn11.1%
Pharmacy and specialty retail24.0%20.1%USD 78 mn8.1%
Clinics and practitioners12.0%12.1%USD 39 mn10.1%
Other channels8.0%6.1%USD 26 mn7.1%

By purity grade

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
95 to 98 percent31.0%26.0%USD 101 mn8.1%
98 to 99 percent44.0%44.0%USD 144 mn10.0%
Above 99 percent25.0%30.0%USD 82 mn12.0%

By production route

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Enzymatic synthesis41.0%46.0%USD 134 mn11.3%
Chemical synthesis33.0%26.0%USD 108 mn7.4%
Microbial fermentation26.0%28.0%USD 85 mn10.8%

By user group

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Adults 35 to 5441.0%38.0%USD 134 mn9.2%
Seniors 55 and over37.0%41.0%USD 121 mn11.1%
Athletes and younger biohackers22.0%21.0%USD 72 mn9.5%

Top 25 countries for NMN (nicotinamide mononucleotide) by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 89.0% of 2026 revenue and the 25 countries below together hold 97.0%.

Exhibit 4United States is the largest country market at USD 111 mn in 2026, and the three largest countries hold 64.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
NMN (Nicotinamide Mononucleotide) market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 111 mn, 34.0%; Japan: USD 65 mn, 20.0%; China: USD 33 mn, 10.0%; South Korea: USD 20 mn, 6.0%; Taiwan: USD 16 mn, 5.0%; Hong Kong: USD 13 mn, 4.0%; Singapore: USD 9.8 mn, 3.0%; Australia: USD 9.8 mn, 3.0%; United Kingdom: USD 6.5 mn, 2.0%; Germany: USD 6.5 mn, 2.0%.United States111 mn 34.0%Japan65 mn 20.0%China33 mn 10.0%South Korea20 mn 6.0%Taiwan16 mn 5.0%Hong Kong13 mn 4.0%Singapore9.8 mn 3.0%Australia9.8 mn 3.0%United Kingdom6.5 mn 2.0%Germany6.5 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 111 mn34.0%USD 299 mn10.4%
2JapanUSD 65 mn20.0%USD 139 mn7.8%
3ChinaUSD 33 mn10.0%USD 105 mn12.4%
4South KoreaUSD 20 mn6.0%USD 53 mn10.4%
5TaiwanUSD 16 mn5.0%USD 42 mn9.8%
6Hong KongUSD 13 mn4.0%USD 32 mn9.4%
7SingaporeUSD 9.8 mn3.0%USD 26 mn10.4%
8AustraliaUSD 9.8 mn3.0%USD 26 mn10.4%
9United KingdomUSD 6.5 mn2.0%USD 14 mn8.2%
10GermanyUSD 6.5 mn2.0%USD 14 mn8.2%
11CanadaUSD 5.0 mn1.5%USD 13 mn10.3%
12FranceUSD 3.4 mn1.0%USD 9.0 mn10.3%
13ItalyUSD 2.6 mn0.8%USD 6.9 mn10.3%
14SpainUSD 2.1 mn0.7%USD 5.7 mn10.3%
15NetherlandsUSD 1.8 mn0.6%USD 4.8 mn10.2%
16MalaysiaUSD 1.6 mn0.5%USD 4.9 mn11.9%
17ThailandUSD 1.4 mn0.4%USD 4.4 mn11.8%
18SwitzerlandUSD 1.3 mn0.4%USD 3.5 mn10.3%
19BrazilUSD 1.2 mn0.4%USD 3.6 mn11.7%
20MexicoUSD 1.1 mn0.3%USD 3.0 mn10.3%
21IndiaUSD 1.1 mn0.3%USD 3.1 mn11.6%
22United Arab EmiratesUSD 0.98 mn0.3%USD 3.0 mn11.7%
23IsraelUSD 0.92 mn0.3%USD 2.5 mn10.4%
24SwedenUSD 0.88 mn0.3%USD 2.4 mn10.4%
25VietnamUSD 0.85 mn0.3%USD 2.5 mn11.6%
Rest of worldUSD 9.7 mn3.0%USD 25 mn9.9%
Exhibit 5United States and Japan account for 50% of the USD 521 mn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
NMN (Nicotinamide Mononucleotide) market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 327 mn. United States: +USD 187 mn; Japan: +USD 74 mn; China: +USD 72 mn; South Korea: +USD 33 mn; Taiwan: +USD 25 mn; 20 other countries: +USD 114 mn; Rest of world: +USD 15 mn. Market value 2036: USD 848 mn.Market value 2026327 mnUnited States+187 mnJapan+74 mnChina+72 mnSouth Korea+33 mnTaiwan+25 mn20 other countries+114 mnRest of world+15 mnMarket value 2036848 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Shenzhen Hawkins
  • GeneHarbor
  • Effepharm
  • Kingdomway
  • Metro International Biotech

Group 2: Regional and specialist players

  • ProHealth Longevity
  • DoNotAge
  • Jinfiniti Precision Medicine
  • Nuchido
  • Qualia Life Sciences
  • Thorne HealthTech

Group 3: Emerging and niche players

  • Renue By Science
  • Alive By Science

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the NMN (nicotinamide mononucleotide) market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.

The market is divided by form, by channel, by purity grade, by production route, by user group. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the NMN (nicotinamide mononucleotide) market?

The global NMN (nicotinamide mononucleotide) market is estimated at USD 300 mn in 2025 and USD 327 mn in 2026.

How fast will the NMN (nicotinamide mononucleotide) market grow?

It is forecast to reach USD 848 mn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 521 mn.

Which country is the largest market for NMN (nicotinamide mononucleotide)?

United States is the largest market by revenue at USD 111 mn in 2026, 34.0% of the global total. The three largest countries together hold 64.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 12.4% a year from 2026 to 2036.

Which NMN (nicotinamide mononucleotide) segment is largest?

In the by form split, Capsules and tablets is the largest segment with 52.0% of 2026 revenue.

Who are the leading NMN (nicotinamide mononucleotide) companies?

Global leaders include Shenzhen Hawkins, GeneHarbor, Effepharm, Kingdomway.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Food and Beverage

← NAD Precursor Supplements Natural Antioxidant →

All Food and Beverage markets →

Request a sample